Chronic hepatitis C Liver fibrosis Vitamin D Liver fibrosis Chronic hepatitis C TGF-
Conditions
Interventions
Ergocalciferol,Placebo
Experimental Drug,Placebo Comparator Drug
vitamin D,placebo
Sponsors
The Gastroenterological Association of Thailand
Chulalongkorn university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years Chronic hepatitis C with sustained virologic response after direct-acting agent Evidence of liver fibrosis from fibroscan, MRE or ultrasound
Exclusion criteria
Exclusion criteria: Decompensated liver cirrhosis Chronic liver disease or cirrhosis from other causes HIV infection, autoimmune disease, malignancy, asthma or COPD Pregnancy and/or lactation woman Active viral or bacterial infection History of steroids or immunosuppressive therapy in 6 months before enrollment History of interferons-based therapy within 1 year History of active alcohol drinking in 6 months before enrollment Chronic kidney disease (GFR ≤ 60 ml/min)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of TGFbeta1 6 weeks ng/ml | — |
Secondary
| Measure | Time frame |
|---|---|
| change of TIMP1, MMP2, MMP9 6 weeks ng/ml | — |
Countries
Thailand
Contacts
Public Contactsupachaya sriphoosanaphan
Chulalongkorn university
Outcome results
None listed